FDA imposed a clinical hold on Gilead Sciences’ multiple trials involving its experimental long-acting HIV combination pills after participants exhibited declines in immune cell counts, raising potential safety issues. This pause disrupts the development timeline of these treatments and casts uncertainty over their future regulatory approval prospects.